The HIV-1 (Human Immunodeficiency Virus) is a member of the retroviral family which contains a single- stranded RNA genome and is the major etiological agent involved in the development of acquired immunodeficiency syndrome or AIDS. The World Health Organization now estimates that in 2016 over 40 million people worldwide are infected. The most recent CDC report estimates that in the US over 1.2 million people are infected including about 13% who are unaware of their infections. With the development of antiretroviral therapy (ART), there has been much needed progress over the past decade. The challenge of targeting persistent reservoirs of the virus that are associated with HIV latency remains a daunting challenge to developing an effective cure. It is possible that direct cell-to-cell transmission of HIV may play a role in maintaining persistent reservoirs associated with lymphatic tissues. Preventing this mode of viral spread may be a key aspect in developing effective combination therapies for true viral eradication. There are a number of potential targets in the life cycle of the HIV virus including HIV reverse transcriptase (RT), HIV protease, and more recently viral entry, attachment, and integration. Drugs targeting RT remain a cornerstone of AIDS therapy in most therapeutic regimens. The drugs that target HIV-1 RT are divided into two classes: nucleoside inhibitors (NRTIs) and non-nucleoside inhibitors (NNRTIs). The rapid development of drug resistance by the error prone RT, side effects, and issues of viral vs host polymerase selectivity necessitate the discovery of more effective NRTIs and NNRTIs with improved safety, pharmacological, and drug resistance profiles. Building on the discovery of a very potent novel lead compound, using computationally, mechanism, and structure-guided design, the PI and an established set of collaborators, have used lead optimization to develop three new classes of novel NNRTIs. These new NNRTIs have excellent potency on WT and drug resistant strains of HIV, optimal pharmacological properties, and synergy with clinically relevant NRTIs. Comprehensive studies are described to develop these compounds into preclinical candidates that might be useful in combination therapy as well as for eradication of persistent HIV reservoirs.

Public Health Relevance

The World Health Organization estimates that in 2016 almost 40 million people worldwide are infected with HIV. There continues to be a significant need for new drugs and drug combinations to combat this disease. A great deal of effort to develop drugs against HIV has centered around the molecular target, HIV reverse transcriptase (RT). The studies outlined in this proposal will combine mechanistic studies with computational and structural guidance to design more effective therapies that have improved therapeutic properties.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM049551-26
Application #
9488503
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Barski, Oleg
Project Start
1993-04-01
Project End
2020-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
26
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Kudalkar, Shalley N; Beloor, Jagadish; Quijano, Elias et al. (2018) From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci U S A 115:E802-E811
Baranovskiy, Andrey G; Duong, Vincent N; Babayeva, Nigar D et al. (2018) Activity and fidelity of human DNA polymerase ? depend on primer structure. J Biol Chem 293:6824-6843
Chan, Albert H; Lee, Won-Gil; Spasov, Krasimir A et al. (2017) Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. Proc Natl Acad Sci U S A 114:9725-9730
Kudalkar, Shalley N; Beloor, Jagadish; Chan, Albert H et al. (2017) Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Mol Pharmacol 91:383-391
Li, Min; Mislak, Andrea C; Foli, Yram et al. (2016) The DNA Polymerase Gamma R953C Mutant Is Associated with Antiretroviral Therapy-Induced Mitochondrial Toxicity. Antimicrob Agents Chemother 60:5608-11
Mislak, Andrea C; Anderson, Karen S (2016) Insights into the Molecular Mechanism of Polymerization and Nucleoside Reverse Transcriptase Inhibitor Incorporation by Human PrimPol. Antimicrob Agents Chemother 60:561-9
Lee, Won-Gil; Frey, Kathleen M; Gallardo-Macias, Ricardo et al. (2015) Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 25:4824-7
Frey, Kathleen M; Puleo, David E; Spasov, Krasimir A et al. (2015) Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J Med Chem 58:2737-45
Sohl, Christal D; Szymanski, Michal R; Mislak, Andrea C et al. (2015) Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase ?. Proc Natl Acad Sci U S A 112:8596-601
Muftuoglu, Yagmur; Sohl, Christal D; Mislak, Andrea C et al. (2014) Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics. Antiviral Res 106:1-4

Showing the most recent 10 out of 51 publications